| 1  | Comparative gene regulatory networks modulating APOE expression in microglia  |   |
|----|---|---|
| 2  | and astrocytes  |   |
| 3  |   |   |
| 4  | Logan Brase <sup>1,2</sup> , Yanbo Yu <sup>1,2</sup> , Eric McDade <sup>3</sup> , Dominantly Inherited Alzheimer Network (DIAN)°, |   |
| 5  | Oscar Harari <sup>1,2,4,¶</sup> , Bruno A. Benitez <sup>5,¶,*</sup>   |   |
| 6  |   |   |
| 7  | Affiliations:   |   |
| 8  | 1.  | Department of Psychiatry, Washington University, Saint Louis, St. Louis, Missouri, United States of America |
| 9  | 2.  | The Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University, St. Louis,       |
| 10 |   | Missouri, United States of America  |
| 11 | 3.  | Department of Neurology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA          |
| 12 | 4.  | Department of Neurology, Division of Neurogenetics, The Ohio State University, Columbus, OH, United States  |
| 13 |   | of America  |
| 14 | 5.  | Department of Neurology and Neuroscience, Harvard Medical School and Beth Israel Deaconess Medical          |
| 15 |   | Center, Boston, Massachusetts, United States of America   |
| 16 |   |   |
| 17 | ° A list of authors and their affiliations appears at the end of the paper.   |   |
| 18 | <sup>¶</sup> Equally contributing senior author   |   |
| 19 | * Corresponding author  |   |

20 E-mail: bbenitez@bidmac.harvard.edu

## 21 Abstract

Background: Single-cell technologies have unveiled various transcriptional states in different
 brain cell types. Transcription factors (TFs) regulate the expression of related gene sets, thereby
 controlling these diverse expression states. Apolipoprotein E (APOE), a pivotal risk-modifying

- 25 gene in Alzheimer's disease (AD), is expressed in specific glial transcriptional states associated
- 26 with AD. However, it is still unknown whether the upstream regulatory programs that modulate
- 27 its expression are shared across brain cell types or specific to microglia and astrocytes.
- 28
- 29 Methods: We used pySCENIC to construct state-specific gene regulatory networks (GRNs) for
- 30 resting and activated cell states within microglia and astrocytes based on single-nucleus RNA
- 31 sequencing data from AD patients' cortices from the Knight ADRC-DIAN cohort. We then
- 32 identified replicating TF using data from the ROSMAP cohort. We identified sets of genes co-
- regulated with *APOE* by clustering the GRN target genes and identifying genes differentially
- 34 expressed after the virtual knockout of TFs regulating APOE. We performed enrichment analyses
- 35 on these gene sets and evaluated their overlap with genes found in AD GWAS loci.
- 36
- 37 **Results**: We identified an average of 96 replicating regulators for each microglial and astrocyte
- cell state. Our analysis identified the CEBP, JUN, FOS, and FOXO TF families as key regulators of
- 39 microglial APOE expression. The steroid/thyroid hormone receptor families, including the THR
- 40 TF family, consistently regulated APOE across astrocyte states, while CEBP and JUN TF families
- 41 were also involved in resting astrocytes. AD GWAS-associated genes (*PGRN*, *FCGR3A*, *CTSH*,
- 42 ABCA1, MARCKS, CTSB, SQSTM1, TSC22D4, FCER1G, and HLA genes) are co-regulated with
- 43 APOE. We also uncovered that APOE-regulating TFs were linked to circadian rhythm (*BHLHE40*,
- 44 DBP, XBP1, CREM, SREBF1, FOXO3, and NR2F1).
- 45
- 46 **Conclusions**: Our findings reveal a novel perspective on the transcriptional regulation of *APOE* in
- 47 the human brain. We found a comprehensive and cell-type-specific regulatory landscape for
- 48 APOE, revealing distinct and shared regulatory mechanisms across microglia and astrocytes,
- 49 underscoring the complexity of APOE regulation. APOE-co-regulated genes might also affect AD
- 50 risk. Furthermore, our study uncovers a potential link between circadian rhythm disruption and
- 51 *APOE* regulation, shedding new light on the pathogenesis of AD.
- 52
- 53

54 Keywords: Alzheimer Disease, APOE, single-nucleus RNA-seq, gene regulatory networks,

55 microglia, astrocyte

Alzheimer disease (AD) is a progressive neurodegenerative disorder that affects millions of

## 56 Introduction

57

58 people worldwide. It is characterized by cognitive impairment, memory loss, and behavioral 59 changes. The strongest genetic risk modifiers are variants in the gene APOE. It is involved in lipid 60 transport and metabolism in the brain and has two primary variants that influence disease risk, 61 e2 (protective) and e4 (risk). APOE is constitutively expressed in astrocytes and activated 62 microglia<sup>1</sup>, cell types that are key players in neuroinflammation and neurodegenerative 63 processes<sup>2</sup>. 64 When activated, microglial cells can significantly upregulate APOE expression, a process that is 65 crucial for the phagocytic clearance of amyloid-beta and other debris<sup>3</sup>. Astrocytes, utilize APOE 66 to support the lipid and energy demands of the surrounding neurons<sup>4</sup>. The  $\varepsilon$ 4 allele, in 67 particular, has been associated with a detrimental effect on microglial activation and astrocytic 68 function, exacerbating neuroinflammatory and neurodegenerative processes<sup>2–4</sup>. These 69 expression states are not static; they evolve in response to the brain's pathological environment, 70 influencing disease progression and severity. Understanding the differences in APOE expression 71 regulation between microglial and astrocytic cell states can provide valuable insights into the 72 molecular mechanisms underlying APOE's involvement in AD and potentially other 73 neurodegenerative disorders. 74 In this study, we aimed to further investigate the differences in the regulation of APOE 75 expression between various microglial and astrocytic cell states using single-nucleus RNA-seq 76 (snRNA-seq). To this end, we performed state-specific gene regulatory network (GRN) analysis

vsing pySCENIC on specific cell states (Figure 1). We then used two approaches to identify gene

sets co-regulated with APOE in these networks: co-regulatory network clusters and transcription

79 factor knockout (TF-KO) differentially expressed genes (DEGs). We assessed the relevance of

80 these gene sets to AD by testing their overlap with AD genome-wide association study (GWAS)

81 genes and their enrichment in AD-related pathways. By delineating the GRNs in these critical

82 cell states, we seek to elucidate the distinct transcriptional regulatory mechanisms that govern

83 APOE expression, which is crucial for unraveling the complex interplay between APOE regulation

84 and AD pathogenesis. This knowledge may lead to the development of targeted therapeutic

- 85 interventions to modulate APOE-related biology in specific cell types to mitigate disease
- 86 progression.



87

- 88 Figure 1 Analysis workflow
- 89 We extracted microglial and astrocytic cell states and ran them individually through pySCENIC to create state-specific GRNs. We
- 90 replicated the putative pySCENIC-TFs by integrating microglia and astrocytes from the ROSMAP cohort and running pySCENIC on
- 91 them. We clustered the target genes into co-regulatory networks and virtually knocked out the transcription factors (TF KO) that
- 92 regulated APOE. We identified genes co-regulated with APOE using co-regulatory network clusters and TF-KO DEGs. Both sources
- 93 of gene sets were tested for inclusion of AD GWAS genes and gene set enrichment.

94

## 95 Results

#### 96 Cell-state-specific transcription factors modulating APOE expression

- 97 To identify the state-specific TF regulators of APOE, we utilized snRNA-seq data from the Knight
- 98 ADRC and DIAN cohorts (parietal, n=67)<sup>5</sup>, and replicated the TFs in snRNA-seq from the
- 99 ROSMAP cohort (dorsolateral prefrontal cortex, n=32)<sup>6</sup>. Focusing on microglia and astrocytes,
- 100 the principal *APOE* expressors<sup>1</sup>, we isolated the resting and activated states for each cell type:
- 101 mic-resting (n=7,032), mic-activated (n=3,662), mic-inflammatory (n=1,669), astro-resting
- 102 (n=21,010), and astro-activated (n=10,028). We leveraged pySCENIC<sup>7</sup> to build a GRN for each
- state, and detected an average of 117 and 109 reproducible TF regulators for Knight and
- 104 ROSMAP cohorts respectively (Supplementary Table 1). We compared the putative TFs between
- the cohorts and identified an average of 96 replicating regulators for each cell state (Figure 2,
- 106 Supplementary Table 1). Among these, 35 TFs were shared by all five states, including ARID3A
- 107 (ABCA7 locus), GABPA (APP locus), and MAF (WWOX locus), which are within AD GWAS loci<sup>8</sup>
- 108 (Supplementary Table 2). Moreover, 59 TFs were shared by the microglia states, including SPI1,
- 109 IKZF1, TCF3 (KLF16 locus), and GABPB1 (SPPL2A locus), which are within AD GWAS loci<sup>8,9</sup>, and
- 110 69 TFs were shared by the astrocyte states including *SREBF1* (*MYO15A* locus) and *ZNF518A*
- 111 (BLNK locus).



#### 112

113 Figure 2 Inclusive intersection of state-specific TF regulators

114 TF sets were identified by individually running pySCENIC on the Knight/DIAN and ROSMAP cell states and isolating the

115 intersecting TFs between the discovery and replication runs (see Methods). The TF sets were then compared in an upset plot. The

116 inclusive intersection indicates that all subsets are counted in the superset. For example, all 35 TFs shared between all cell states

117 (the lowest subset) are counted in all other sets. The red column indicates the TFs that are common between all microglia states.

**118** The blue column indicates that TFs that are common between both astrocyte cell states.

#### **Different TF families regulate APOE between microglia and astrocytes**

- 120 Next, we pinpointed the TFs regulating APOE in each state. In the mic-resting GRN, APOE was
- 121 regulated by CEBPA, CEBPB, CEBPD, IRF7, and JUND TFs. In the mic-activated and mic-
- 122 inflammatory GRNs, APOE was regulated by CEBPB, CEBPD, and JUNB, with IRF7 also involved in
- 123 the mic-activated state. In the astrocytic GRNs, APOE was regulated by JUN and THRA in the
- 124 resting state and by *THRB* in the activated state.
- 125 These results highlight the CCAAT/enhancer-binding protein (CEBP) family of TFs, which form
- 126 homo- and heterodimers to precisely control the expression of target genes that are primarily
- 127 immune-related<sup>10</sup>. In mouse microglia cell cultures, *CEBPA* was shown to regulate homeostatic
- and anti-inflammatory DAM genes<sup>11</sup>, and in mouse models, *CEBPB* modulates *APOE*
- 129 expression<sup>12</sup>. These findings validate pySCENIC's ability to capture known biology and lends
- 130 credence to the other findings. In addition, *CEBPD* was shown to boost the expression of
- activation genes, including *NOS2*, *C6*, *IL1B*, and *IL6* in a BV2 microglia cell line<sup>13</sup>. Intriguingly, LPS
- 132 treatment upregulates *CEBPB* and *CEBPD* while downregulating *CEBPA*, implying contrasting
- 133 regulatory functions. This could account for CEBPA's role as an APOE regulator only in mic-
- 134 resting, but not in mic-activated and mic-inflammatory.
- 135 IRF plays a crucial role in the immune response. *IRF7* regulates type I interferon genes and *IL6*<sup>14</sup>.
- 136 The JUN family proteins are known to be involved in various cellular processes, including
- 137 proliferation, apoptosis, and immune response<sup>15</sup>. Their role in regulating *APOE* expression
- 138 suggests a potential link between *APOE* and these cellular processes.
- 139 Thyroid hormone receptor family proteins, including *THRA* and *THRB*, bind to thyroid hormone,
- 140 which plays a crucial role in metabolism, growth, and development. Using cell lines, *THRB* was
- shown to upregulate APOE expression in astrocytes by forming a complex with RXRA and
- 142 binding to the multienhancer ME.2 which activates the APOE promoter<sup>16</sup>. Once again, this
- 143 shows that pySCENIC identifies true regulatory relationships.
- 144 Our findings suggest that *CEBPB* and *THRB* regulate *APOE* expression in the human brain, in
- 145 concordance with studies in model systems. The GRNs from pySCENIC suggest that the CEBP
- 146 family primarily regulates *APOE* in microglia, while the THR family chiefly regulates expression in
- 147 astrocytes. This is in line with CEPB regulating immunity genes and microglia being the primary

- immune cells in the brain, as well as THR influencing metabolism and astrocytes being the
- primary support cells for neurons. This does not exclude the possibility that both families may
- 150 influence APOE expression in both cell types.
- 151

#### 152 APOE-associated target genes were regulated by TFs linked to the circadian rhythm

We aimed to explore those genes co-regulated with *APOE*. Thus, we built a complex coregulatory network of genes, including all the putative TFs predicted by pySCENIC and their respective regulated genes. Then, we clustered the target genes into a UMAP space using the 86-101 TFs signatures that defined each cell state. We identified an average of 27 gene clusters in each expression state (Figure 3, Supplementary Table 1). The gene clusters containing *APOE* comprised an average of 327 genes regulated by an average of 13 TFs for each cell state (Supplementary Table 1).

- 160 To validate these gene clusters, we isolated the TFs that significantly upregulated the gene
- 161 clusters containing APOE, a known activated marker gene, and CX3CR1 and P2RY12, known
- 162 homeostatic marker genes, in the three microglia clusters. We then performed a virtual
- 163 knockout (KO) of these TFs and observed the shift in the expression profile of the cells.
- 164 We adapted the virtual TF knockout method described in SCENIC+<sup>17</sup> to work with pySCENIC

165 outputs. Following the knockout of the TF, this method propagates the change through the rest

166 of the gene expression matrix (GEM) producing a perturbed expression profile and an

- associated visualization of the shift in the reduced dimensionality space. The TFs regulating
- these homeostatic and activated marker genes should have opposite influences on microglial
- activation, thus opposing shifts in the expression profiles. In the mic-resting state, an individual
- 170 knockout of the TFs associated with the *APOE* gene cluster generally shifted cells toward the
- 171 mic-resting state, indicating these TFs are involved in maintaining an activated state. Conversely,
- individual knockouts of seven of the 14 TFs associated with the *CX3CR1* and *P2RY12* clusters
- 173 generally pointed away from the mic-resting state, suggesting these TFs promote a resting state
- 174 (Supplementary Figure 1). A similar trend was seen within mic-activated, with KO of all 17 APOE
- 175 TFs pointing away from mic-activated and eight of the 19 TFs<sup>CX3CR1/P2RY12+</sup> pointing toward mic-
- activated (Supplementary Figure 2). This indicates that the clustering groups mirror the

expected biology. The mic-inflammatory cluster had no TFs significantly upregulating the
 *CX3CR1* or *P2RY12* clusters, so it was not explored for validation.

179 We then explored the TFs regulating APOE in each state. The mic-resting APOE cluster was 180 regulated by BHLHE40, CEBPG, FOS, FOSL2, GABPA, ILF2, JUN, JUNB, KMT2B, REL, and XBP1, in 181 addition to the TFs directly regulating APOE mentioned previously (Figure 3A, Supplementary Figure 4A). BHLHE40 regulates the circadian rhythm, negatively regulates itself, DBP (another 182 183 circadian gene), and represses RXR, a component of APOE activation through the THR family of TFs<sup>18–21</sup>. BHLHE40 is located within an AD African-American GWAS locus is a key regulator for 184 185 clearing lipid-rich cellular debris by lipid-associated macrophages (LAMs)<sup>8,22</sup>. XBP1 becomes a 186 functional TF in response to endoplasmic reticulum stress induced by unfolded proteins and is modulated by the circadian rhythm<sup>23,24</sup>. The mic-activated APOE cluster included BHLHE40. 187 188 CEBPA, CEBPG, CHD1, CREM, ETS2, FOS, FOSL2, FOXO1, FOXO3, JUND, SP3, SREBF1, and USF2, but not IRF7, compared to APOE alone (Figure 3B, Supplementary Figure 4B). CREM and SREBF1 189 190 are related to circadian rhythm and SREBF1 is additionally related to lipid metabolism<sup>25,26</sup>. 191 Upregulation of FOXO3 and two other TFs, was shown to move weakly inflammatory microglia to a strongly inflammatory state in a cell line<sup>27</sup>. Additionally, FOXO3 is deactivated by SIRT1, 192 another gene associated with circadian rhythm<sup>28</sup>. The mic-inflammatory APOE gene cluster 193 194 added CEBPA, E2F4, FOSL2, GABPB1, HDX, ILF2, IRF7, JUN, JUND, KMT2B, MAF, MAFG, NFE2L1, NR3C1, TCF7L2, and ZBTB40 to the APOE TF list (Figure 3C, Supplementary Figure 4C). E2F4 halts 195 the cell cycle and has been linked to cell quiescence, regulation of AD-related gene networks, 196 and upregulation in AD brains<sup>29</sup>. Macrophage/microglia activation factor (MAF) expression has 197 198 been linked to changes in the endosome/lysosome membranes<sup>30</sup>, which suggests a concerted 199 action between APOE and endo-/lysosomal function in activated microglia. Taken together, the 200 CEBP, FOS, and JUN families regulate the APOE gene clusters across microglial cell states. 201 The APOE clusters within astrocytes were regulated by fewer TFs than their microglial 202 counterparts. Interestingly, astro-resting did not include either of the THR-related TFs. However 203 it included another steroid/thyroid hormone family receptor NR2F1<sup>31</sup> (Figure 3D, 204 Supplementary Figure 4D), which is associated with Bosh-Boonstra-Schaaf optic atrophy 205 (BBSOA), optic nerve atrophy featured by the loss of retinal ganglion cells critical for the light

206 entrainment of the circadian rhythm<sup>32,33</sup>. The APOE cluster in astro-resting also had TFs DBP, 207 CEBPB, ING4, JUND, and TBP (Figure 3D, Supplementary Figure 4D). This supports the idea that 208 the CEBP family of TFs influences APOE in astrocytes and microglia. As previously noted, DBP is 209 related to the circadian rhythm. Astro-activated had MAFG, NFIC, NR2F1, PBX1, POU3F2, RARB, 210 RFX3, and TCF7L1 regulating the APOE gene cluster in addition to THRB which directly regulated 211 APOE in this cell state (Figure 3E, Supplementary Figure 4E). MAFG has been implicated in astrocyte-driven inflammation linked to the chronic inflammatory disease, multiple sclerosis<sup>34</sup>. 212 213 TCF7L1 is important for astrocyte maturation, highlighting the central role that APOE plays in normal astrocyte function<sup>35</sup>. *RARB* is another steroid/thyroid hormone family receptor that 214 215 forms heterodimers with RXR to facilitate transcriptional activation or repression. Despite the 216 absence of the THR-related TFs in astro-resting, both APOE gene clusters were regulated by 217 steroid/thyroid hormone receptors, suggesting expression regulation through thyroid hormone. 218 Overall, we observed that circadian rhythm-related TFs were associated with regulating the APOE gene clusters across cell types and states. This implies that APOE participates in processes 219 220 similar to those regulated by these TFs, even if they do not directly regulate APOE. Alternatively, 221 these TFs may have a role in APOE regulation, but the pySCENIC analysis may lack the power to 222 detect them.



223

224 Figure 3 UMAP representation of gene regulatory networks

A-E) A global UMAP visualization of each cell states' regulome along with a zoomed view highlighting APOE. Principle

226 component analysis was performed on the TF-by-target gene matrix. The top five principal components were used to calculate

the UMAP coordinates. APOE is underlined. The TFs in red directly regulate APOE. TFs in black significantly upregulate the APOE

228 gene cluster. TFs in blue are the TFs that were replicated in the ROSMAP dataset. D) The global UMAP for Astro-resting is

229 zoomed. The full figure can be found in Supplementary Figure 3.

#### 230 Gene set enrichment of APOE gene clusters

231 To investigate the pathways behind the genes within the APOE gene clusters from the co-

- regulatory networks, we performed an enrichment analysis using Gene Ontology (GO) biological
- 233 process (BP) terms. Mic-resting showed an enrichment of pathways related to cytoplasmic
- 234 translation, cytokine production, apoptotic process, integrated stress response,
- immunoglobulin-mediated immune response, response to lipid, IL-6 production, and response
- to LPS (Supplementary Figure 4F, Supplementary Table 3a). Mic-activated shared most of these
- pathways, but also the glycolytic process (Supplementary Figure 4F, Supplementary Table 3b),
- which is a metabolic feature of AD<sup>36</sup>. Mic-inflammatory had fewer pathways than the other two
- 239 microglial states, but they included endocytosis, macroautophagy, and cotranslational protein
- targeting to the membrane (Supplementary Figure 4F, Supplementary Table 3c). These results
- imply that the genes in this cluster are related to the uptake and degradation of extracellular
- 242 material and the replenishment of membrane proteins.
- Astro-resting was enriched for genes in mitochondrial electron transport, NADH to ubiquinone
- and other aspects of the electron transport chain. It also had genes related to Golgi vesicle
- transport and synapse organization (Supplementary Figure 4F, Supplementary Table 3d). These
- results reflect the roles of astrocytes in energy metabolism and synaptic modulation. Astro-
- 247 activated had many genes in its *APOE* cluster (n=409), which made the enrichment analysis less
- 248 sensitive. None of the GO terms passed multiple testing correction, but the top hits (p-value <
- 249 0.01) included terms such as semaphorin-plexin signaling, axon guidance, synapse assembly,
- 250 fatty-acyl-CoA biosynthetic process, glucan catabolic process, and amide metabolic process
- 251 (Supplementary Table 3e). Semaphorin-plexin signaling, in conjunction with axon guidance and
- synapse assembly, suggests an active regulation of the surrounding synapses. Glucan catabolism
- 253 indicates the cell is low on glucose and tapping into glycogen reserves. Fatty-acyl-CoA
- biosynthesis and amide metabolism both indicate that resources are being diverted from ATP
- 255 production through cellular respiration toward the synthesis of lipids like phospholipids and
- cholesterol for membranes and neurotransmitters, which is consistent with previous findings in
- 257 AD<sup>37</sup>.

258 Overall, all microglia states were associated with immune, inflammation, and cytokine-related

terms. We observed that mic-activated and astro-activated cells had genes related to known

260 metabolic alterations in AD. We also noticed that mic-inflammatory and astro-activated cells

- 261 had genes involved in endocytosis and autophagy, which are mechanisms for clearing amyloid-
- 262 beta plaques and recycling other macromolecules.
- 263

## 264 Gene set enrichment of TF target genes

To complement the analysis of the APOE gene clusters, we took a deeper dive into the TFs 265 266 directly regulating APOE. Specifically, we identified the target genes significantly perturbed by a 267 virtual knockout of these TFs. As previously described, we implemented a modified version of 268 the TF-KO method included in SCENIC+, producing a perturbed expression profile after TF-KO. 269 We then performed a Mann-Whitney rank-sum analysis to identify differentially expressed 270 genes between the original and TF-KO GEMs. We found 60 to 434 nominal DEGs for each TF 271 knockout (Supplementary Table 1, Supplementary Table 4). Using the nominal DEGs, we 272 performed a gene set enrichment analysis and visualized the results in a heatmap to better 273 identify patterns in the regulation of biological processes.

274 CEBPB-regulated processes were common across the microglial states, including positive 275 regulation of cytokine production, receptor-mediated endocytosis, and humoral immune 276 response mediated by circulating immunoglobulin (Figure 4, Supplementary Table 5). These 277 processes reflect the role of *CEBPB* in modulating the inflammatory response of microglia. 278 However, CEBPB also regulated processes that were specific to certain microglial states. For 279 example, in mic-inflammatory, CEBPB-regulated genes are involved in mRNA splicing, via 280 spliceosome and cellular response to lipopolysaccharide (Figure 4, Supplementary Table 5). In 281 contrast, in mic-activated, CEBPB lacked the terms related to positive regulation of protein 282 phosphorylation, positive regulation of transferase activity, antigen processing and presentation 283 of exogenous peptide antigen, and cellular response to cytokine stimulus (Figure 4, 284 Supplementary Table 5).

*CEBPD* regulated shared processes in mic-resting and -activated, but had a distinct signature in
 mic-inflammatory. The main divergence between the primary *CEBPB* and *CEBPD* signatures was
 that *CEBPD* additionally regulated fat differentiation, lipoprotein biosynthesis process, and

- 288 positive regulation of small molecule metabolic process (Figure 4, Supplementary Table 5). Mic-
- activated *CEBPD* also regulates the lipid metabolic process. These results suggest that *CEBPD*
- 290 has a more specialized role in regulating genes related to lipid processing than *CEBPB*.



291

Figure 4 Gene set enrichment analysis of the target genes for each cell-state-specific TF regulating APOE
 Target genes for each TF were assessed for GO Biological Process terms. Terms were condensed using Revigo. Rows and columns
 were sorted using hierarchical clustering on Euclidean distance. Tiles with (.) indicate significance after multiple testing
 correction.

- 297 JUNB regulated processes related to the immune response in mic-resting and mic-activated
- 298 states, including negative regulation of the apoptotic process, negative regulation of
- 299 inflammatory response, cellular response to cytokine stimulus, and humoral immune response
- 300 mediated by circulating immunoglobulin (Figure 4, Supplementary Table 5). Within mic-
- 301 activated, it regulated inflammatory response, cellular response to lipopolysaccharide, but also
- 302 synapse pruning and regulation of mRNA splicing, via splicesome indicating that JUNB regulates

303 additional processes other than immune roles in microglia. JUND was the regulator in mic-304 resting state that also regulated negative regulation of apoptotic process and humoral immune 305 response mediated by circulating immunoglobulin, but uniquely among the JUN family, it also 306 regulated negative regulation of amyloid-beta formation through RIN1 and RIN3, which 307 negatively regulate BACE1. This implies that JUND may be beneficial in preventing amyloid-beta 308 accumulation in AD. Within astro-resting, JUN was the regulator and it had the most divergent 309 profile, regulating processes involved in negative regulation of growth, regulation of cell cycle, 310 regulation of cell population proliferation, cellular response to metal ion, and carbohydrate 311 catabolic process (Figure 4, Supplementary Table 5). 312 THRA target genes were not enriched for any particular GO term, but THRB-regulated genes 313 associated with transcription, negative regulation of inclusion body assembly, positive 314 regulation of neurogenesis, cellular response to oxidative stress, axonogenesis, and regulation 315 of cytokinesis (Figure 4, Supplementary Table 5). These processes suggest that THRB regulates 316 genes that prepare astrocytes for activation and inflammatory response. Overall, this alternative 317 method of examining the genes co-regulated with APOE revealed similar immune, lipid, and 318 energy metabolism pathways to those of the APOE gene clusters, strengthening the validity of 319 these biological pathways with APOE. 320

## 321 Additional AD GWAS genes are co-regulated with APOE

The identified TFs that regulate *APOE* also regulate other genes in AD GWAS loci. Using the same set of nominal DEGs identified after the TF KO, we isolated the DEGs that intersected the list of genes within AD GWAS loci. Several of the genes are regulated by multiple *APOE* TFs including *PGRN*, *FCGR3A*, *CTSH*, *ABCA1*, *MARCKS*, *CTSB*, *SQSTM1*, *TSC22D4*, *FCER1G*, and several

of the HLA genes (Figure 5A,B, Supplementary Figure 5).

327 PGRN, CTSH, and CTSB are all related to lysosome function and are co-regulated with APOE in

328 the microglia states. *CTSB* is specifically associated with the proteolytic processing of *APP*<sup>38</sup>.

329 FCER1G and FCGR3A are in the ADAMTS4 locus and encode Fc immunoglobulin receptors that

bind to IgE and IgG respectively. *CEBPB* regulates *FCER1G* in mic-resting and mic-inflammatory.

331 It represses AD risk genes through the Herpes simplex (HSV-1) escape strategy<sup>39</sup>. FCGR3A

332 exacerbates neurodegeneration and is a potential link behind the increased AD risk in chronic 333 periodontitis patients<sup>40,41</sup>. It is regulated in mic-resting by *CEBPB* and *IRF7*; mic-activated by 334 CEBPB and CEBPD; and mic-inflammatory by CEBPB, and JUNB. ABCA1 is a transporter that 335 transfers cholesterol and other lipids to APOE and there is a link between ABCA1, APOE, and A $\beta$ 336 levels<sup>42</sup>. APOE and ABCA1 are co-regulated in both astrocyte and microglial states. MARCKS is 337 associated with lipid rafts, dissociates from the membrane at decreased concentrations of cholesterol, causing PIP2 release, and also influences inflammation<sup>43-45</sup>. SQSTM1 (p62), found in 338 339 the RASGEF1C locus, is also found in both astrocytes and microglia and functions as a bridge 340 between ubiquitinated proteins and autophagosomes<sup>46</sup>. TSC22D4 is within the NYAP1 locus and 341 is regulated in astro-resting by both APOE TFs (THRA and JUN). TSC22D4 participates in forming 342 a complex that degrades *BRI2* and *BRI3*, inhibitors of A $\beta$  production and aggregation. 343 Looking at the APOE gene clusters, we identified genes within the ABCA7 and SCIMP loci across 344 all five cell states and four out of the five states had HLA-DRB1, LILRB2, SIGLEC11, KLF16, 345 DOC2A, and NYAP1 (Figure 5D, Supplementary Figure 5, Supplementary Figure 6). Using SCIMP 346 as an example, mic-resting had gene PFN1 within the APOE gene cluster; mic-activated had 347 CXCL16 and PFN1; mic-inflammatory had CXCL16; astro-resting had SLC25A11; and astro-348 activated had RABEP1 (Figure 5C). Interestingly, PFN1 is related to amyotrophic lateral sclerosis (ALS), action polymerization, and binding of PIP2<sup>47,48</sup>, which could connect it to MARCKS and, 349 350 therefore membrane cholesterol concentrations as mentioned above. CXCL16 induces a 351 chemokine-induced chemotactic response, SLC25A11 maintains the organization and 352 morphology of the mitochondrial cristae<sup>49</sup>, and *RABEP1* is involved in endocytic membrane 353 fusion and recycling of endosomes, all of which connect to AD biology. Genes in AD loci CD33 354 and APH1B were exclusively found in both astrocyte states (Figure 5D). LACTB (APH1B locus) 355 was co-regulated with APOE in astro-resting (Figure 5C) and regulated mitochondrial lipid 356 metabolism<sup>50</sup>. TLN2 (APH1B locus) was co-regulated in astro-activated (Figure 5C) and is a 357 component of the actin cytoskeleton linking to focal adhesion plagues, which have been shown 358 to have higher concentrations of cholesterol than the surrounding membrane<sup>51</sup>. Even though 359 the genes were not necessarily the same across the cell states, the consistency of genes within

- 360 these loci clustering with APOE, and many relating to lipid metabolism, suggests common
- 361 regulatory mechanisms behind these loci and APOE.
- 362 These findings suggest that the regulatory networks involving APOE and the identified
- 363 transcription factors extend beyond *APOE* itself and involve other genes associated with AD.
- 364 Many of these AD-GWAS genes are related to critical immune, lysosome, lipid, and energy
- 365 metabolism pathways highlighted by the previous TF and gene set enrichment analyses. It also
- 366 supports the notion that some GWAS loci have many genes that can simultaneously influence
- 367 AD risk.



368

369 Figure 5 Other AD GWAS genes are coregulated with APOE

370 (A,B) Genes (A) in AD GWAS loci (B) that are co-regulated by APOE-regulating TFs. Genes co-regulated by APOE-TFs were those

differentially expressed (Mann-Whitney Rank U) between the original expression profiles and the perturbed values following
 virtual TF-KO. (C.D) Genes (C) in AD GWAS loci (D) that co-clustered with APOE in the co-regulation networks. Principle

virtual TF-KO. (C,D) Genes (C) in AD GWAS loci (D) that co-clustered with APOE in the co-regulation networks. Principle
 component analysis was performed on the TF-by-target gene matrix. The top five principal components were used to calculate

373 component analysis was performed on the Tr-by-target gene matrix. The top five principal components were used to calculate 374 the UMAP coordinates. Gene clusters were calculated from a shared-nearest-neighbor graph using the Louvain algorithm. Rows

375 are colored by loci. Some genes are within two loci and therefore have two colors. These plots are truncated; the full plots can be

found in Supplementary Figure 6.

377

#### 378 Discussion

379 We used GRNs to elucidate the cell-type- and -state-specific regulation of APOE. These analyses 380 revealed that APOE and its co-regulated genes were modulated by several transcription factor 381 (TF) families, including CEBP, JUN, FOS, FOXO, and THR. The CEBP (A/B/D/B), JUN (/B/D), and 382 FOS (/L2) families were involved in APOE regulation in all microglial states, whereas FOXO (1/3) 383 was specific to the mic-inflammatory state. Despite the consistency of the CEBP, JUN, and FOS 384 families across microglial states, the individual members had different strengths and 385 associations based on cell state suggesting individual TFs could more strongly promote one state 386 over another. The CEBP family of TFs form homo- and heterodimers with each other, so the 387 proportions of these dimers could influence cell state. Additional experimental studies are 388 needed to better understand the interplay between members of these families and how they 389 regulate the activation states of microglia. Interestingly, CEBPB and JUND also regulated the 390 APOE gene cluster in the astro-resting state, suggesting that these TF families play a role in 391 APOE regulation in both microglia and astrocytes. APOE in astro-activated was controlled by the known APOE regulator THRB<sup>16</sup>, and NR2F1 and RARB, two other members of the steroid/thyroid 392 393 hormone receptor family. We previously reported an upregulation of *THRB* in the mic-activated 394 state compared to the other microglia states, implying that the THR family of TFs could 395 influence APOE expression in microglia as well, but to a lower degree<sup>5</sup>. Further studies are 396 required to confirm this conclusion.

397 These GRNs identified associations with immunoglobulin binding, IL1B/IL6/cytokine production, 398 glycolysis, endocytosis, macroautophagy, mitochondrial electron transport, fatty-acyl-CoA 399 biosynthesis, glucan catabolism, and amide metabolism. Related to immunoglobulin binding, AD 400 GWAS associated genes FCER1G, FCGR2A, and FCGR3A are Fc immunoglobulin receptors that 401 bind to IgE and IgG and were coregulated with APOE in microglia. Usually, IgE and IgG cannot 402 cross the blood-brain-barrier (BBB), but it has been suggested that in APOEe4 carriers, the 403 vasculature and endothelial cells making up the BBB are compromised, and albumin, antibodies, 404 cytokines, and other inflammatory molecules more easily cross into the brain<sup>52,53</sup>. This might account for the association between this biology and APOE. It might also explain how 405 406 periodontitis, a peripheral infection, could increase AD risk in association with  $FCGR3A^{41}$ .

407 Additionally, when microglia and astrocytes encounter these inflammatory signals, they 408 propagate the signal by producing their own IL1B, IL6, and other cytokines, as suggested by 409 these GRNs<sup>54–56</sup>. Astrocytes also boost their cholesterol production in response to cytokine signaling<sup>53</sup>. Within astro-activated, we saw many APOE-related genes pointing to fatty-acyl-CoA 410 411 biosynthesis, a precursor to cholesterol. APOE is one of the key molecules transporting this 412 newly synthesized cholesterol to the surrounding cells. Evidence indicates that increases in 413 cholesteryl ester, the storage molecule for excess cholesterol, increase the accumulation of phosphorylated tau (pTau) by reducing the proteasome protein units<sup>57,58</sup>. Studies have also 414 suggested that this increased cholesterol enlarges the lipid rafts, influencing many associated 415 416 receptors<sup>53,59,60</sup>. For instance, APP, BACE1, TREM2, MS4A, TLR4, Fc immunoglobulin receptors, and *GLUT1* are all associated with lipid rafts<sup>53,59–61</sup>. Our analysis shows that other AD GWAS 417 418 genes are co-regulated with APOE; some are also associated with cholesterol levels in the 419 membrane, including MARCKS, PRN1, and TLN2. In neurons, APP is upregulated and 420 preferentially beta-cleaved when associated with lipid rafts which is amyloidogenic<sup>59,60</sup>. TREM2, 421 TLR4, IFNGR, and TNFA are all receptors that rely upon clustering as a part of their activation<sup>53</sup>, 422 and increased cholesterol mediates this clustering, enhancing the activation of these cells, again 423 highlighting the connection between cytokines and the APOE-related genes. Astrocytes are the 424 primary support cells of the brain and are in contact with the vasculature to facilitate the uptake 425 and delivery of essential molecules to the neurons and other cells. GLUT1 transports glucose 426 into astrocytes through the endfeet, but evidence suggests that *GLUT1* is less efficient when 427 incorporated into large lipid rafts induced by increased cholesterol<sup>62,63</sup>. This might explain why 428 the mitochondrial electron transport chain is associate with astro-resting, while glucan 429 catabolism, or the breakdown of glycogen into glucose, is linked to astro-activated state. Other 430 studies have reported a reduction in glucose uptake in AD<sup>36</sup>. Interestingly, while extra 431 cholesterol decreases glucose uptake, it increases neuronal energy demand by promoting 432 neurotransmitter release in presynapses and the endocytosis and internalization of receptors in 433 postsynapses<sup>64</sup>. This energy demand stimulates the transport of lactate and ketones from 434 astrocytes to neurons, enabling increased neural activation by bypassing the rate-limiting step of glycolysis in energy production<sup>36,65</sup>. Evidence shows that in young APOEe4 carriers, there is an 435

436 increase in cognitive performance and neuronal activity, suggesting this biology is 437 occurring<sup>36,66,67</sup>. With age we see the negative aspects of this increased neuronal activity. 438 Neuronal activity produces reactive oxygen species (ROS), so these hyperactive neurons 439 produce increased quantities of ROS which then peroxidate the fatty acids (pFA) found in the 440 cell and organelle membranes<sup>68</sup>. These pFA are toxic, so the neurons expel them with the help of APOE. Over time, ROS and pFA build up in the neuron, causing neurotoxicity, especially in 441 442 APOEe4 carriers with less efficient binding and, therefore, export of lipids. The expelled pFA is 443 then picked up by microglia and astrocytes and stored in lipid droplets (LD), which is consistent with our finding GO terms, TFs (MAF and CEBPB), and GWAS genes (RABEP1) related to 444 445 endocytosis. This is also concordant with our finding that BHLHE40, a regulator for the clearance 446 of lipid-rich cellular debris, is an APOE regulator. Excess cholesterol produced by astrocytes also 447 collects in the lysosome, where it causes lysosomal dysfunction, leading to the buildup of autophagosomes and mitochondrial dysfunction<sup>36</sup>. This is consistent with many of the co-448 regulated GWAS genes we identified, including PGRN, CTSH, CTSB (lysosome), SQSTM1 449 450 (autophagosomes), SLC25A11, and LACTB (mitochondria metabolism). 451 Our findings also show that many TFs regulating APOE and the APOE gene clusters are related to 452 circadian rhythm, including BHLHE40, DBP, XBP1, CREM, SREBF1, FOXO3, and NR2F1. This is 453 consistent with many studies that have reported an association between AD and disrupted 454 sleep due to circadian rhythm dysfunction<sup>33,66,69–71</sup>. These findings highlight the importance of 455 the circadian rhythm in regulating APOE expression and function. Interestingly, NR2F1 is 456 associated with BBSOA, a neurodevelopmental disease characterized by the loss of retinal 457 ganglion cells<sup>32</sup>. Another study with APOE<sup>-/-</sup> reported the loss of melanopsin-expressing ganglion cells in the suprachiasmic nucleus, resulting in the loss of light entrainment<sup>33</sup>, the process by 458 459 which light synchronizes the biological clock with the environment. These studies suggest that 460 *NR2F1* and *APOE* are connected and involved in the circadian rhythm, as indicated by our GRNs. 461 Furthermore, the disruption of energy metabolism and the suggested increase in ketone metabolism are modulated by AMPK<sup>72</sup>. AMPK also degrades the circadian proteins Per and Cry, 462 which are produced by the transcriptional activation of *Clock* and *Bmal1*<sup>73</sup>. *Per* and *Crv* form a 463 464 complex with CK1E/D and inhibit the transcription of Clock, Bmal1, Per, and Cry, creating a

465 negative feedback loop. The degradation of Per and Cry by AMPK breaks this loop and results in 466 the overexpression of *Clock* and *Bmal1*, as well as their downstream targets, such as *NR1D1*, 467 which encodes the Rev-ERB $\alpha$  protein. NR1D1 represses Cx3cr1, a marker of homeostatic 468 microglia, thus activating microglia and influencing lipid droplet formation<sup>74,75</sup>. Disruption of the 469 circadian rhythm is associated with impaired function and integrity of the endothelial and 470 vascular smooth muscle cells, causing inflammation and passing these inflammatory markers through a weakened BBB<sup>73</sup>. It is also related to energy metabolism during the fasting stage of 471 sleep<sup>26</sup>. Overall, our results reemphasize the connection of AD to circadian rhythm and suggest 472 473 that APOE and lipid biology are key contributors.

474 In general, the TF families primarily associated with microglia suggest a relationship between 475 immunity and APOE, while the TF family associated with astrocytes suggests a link between 476 APOE and lipid metabolism. This is consistent with the primary function of each of these cell 477 types. In astrocytes, the evidence points to the primary purpose of APOE in lipid metabolism is 478 to shuttle cholesterol and other lipids synthesized by the astrocytes to other cells. The primary 479 purpose of APOE in immunity is not quite as clear in microglia. A promising possibility is the 480 secretion of extracellular vesicles (EVs) that are induced upon microglial activation. The biology 481 related to these EVs is closely tied with that of the endosomal-lysosomal system<sup>76</sup>, highlighted 482 in our GRNs. These EVs can contain RNA, protein, lipids, and cytokines for extracellular communication<sup>77</sup>. A study in *Apoe<sup>-/-</sup>* mice on a high-fat diet highlighted the role of *Apoe* in 483 484 influencing the miRNA composition of EVs secreted by these macrophages and their impact on 485 atherosclerosis<sup>78</sup>. Although most studies on EVs interrogate their miRNA composition, other 486 studies suggest differences in lipid composition based on microglia state as well<sup>79</sup>, including 487 increased secretion of cholesterol in EVs in response to increased free cholesterol<sup>80</sup>. APOE could 488 play a role in the transfer of lipids to these EVs.

A limitation of this study is that pySCENIC utilizes only a single modality, co-expression, to
identify relationships between TFs and target genes, unlike the newer SCENIC+, which also
incorporates chromatin accessibility. Despite this, pySCENIC has successfully identified
biologically relevant TF-target interactions. We presume that TFs regulating the *APOE* gene
clusters within the co-regulatory networks influence APOE, even in the absence of direct TF-

- 494 APOE links in the pySCENIC results. Nevertheless, the findings underscore many known features
- 495 of AD and establish a link to APOE biology. Moreover, the discovery cohort includes carriers of
- 496 APOE, TREM2, APP, and PSEN1 variants, all of which could influence the GRNs in ways not
- 497 accounted for. Additionally, the cohort's European ancestry may restrict the generalizability of
- 498 these results to other, less represented populations.
- 499 In conclusion, the TFs and pathways associated with *APOE* all support known AD pathology and
- 500 support the building evidence implicating lipids as a key driver of AD-related pathology.

501

## 502 Methods

#### 503 Single nucleus RNA-seq acquisition and integration

504 Human snRNA-seq data of the parietal lobe from the Knight ADRC and DIAN was gathered at

- 505 NIAGADs (accession number <u>NG00108</u>) and upon request from DIAN. These data include a total
- 506 of 67 neuropathological controls, sporadic AD, and autosomal dominant AD participants.
- 507 An independent human snRNA-seq dataset from ROSMAP (dorsolateral prefrontal cortex) was
- 508 collected from Synapse (synapse ID syn21125841). The ROSMAP data has 11 sporadic AD,
- 509 11 TREM2 R62H, and 10 control participants. The microglia from the ROSMAP dataset was
- 510 previously integrated with the microglia from the Knight and DIAN data<sup>5</sup>. The ROSMAP
- astrocytes were integrated as a part of this study using the same process described by Brase, *et*
- 512 *al.* Briefly, we isolated and normalized the astrocytes with Seurat's (v.4.3.0) *SCTransform*, setting
- 513 "return.only.var.genes" to FALSE and regressing out "nCount\_RNA" and "nFeature\_RNA". We
- 514 integrated the astrocytes with 3000 features in *SelectIntegrationFeatures*, *PrepSCTintegration*,
- 515 our data as reference in *FindIntegrationAnchors*, and *IntegrateData*. We clustered integrated
- 516 data with ten principal components in *FindNeighbors* and resolution 15 in *FindClusters*. We gave
- 517 each cluster an 'original' identity by isolating our nuclei from clusters and finding the most
- 518 common original ID. We transferred this ID to ROSMAP nuclei like a k-nearest neighbor classifier.
- 519 We mapped cluster identities to pre-integrated normalized ROSMAP data.
- 520

#### 521 Gene regulatory network prediction by pySCENIC

We created cell-state-specific GRNs using the python implementation of the SCENIC<sup>81</sup> analysis 522 523 method called  $pySCENIC^7$  (version 0.12.1). We isolated the cell type of interest and filtered the 524 genes to those that were expressed in  $\geq$ 5% of the cell type population. Then we isolated the cell 525 expression states of interest. We ran pySCENIC on each individual cell state 100 times (different 526 seed for each run) as suggested by pySCENIC. We employed default values for all parameters 527 and provided default reference data downloaded from https://resources.aertslab.org/cistarget/: 528 Database (hg38 500bp up 100bp down full tx v10 clust.genes vs motifs.rankings, 529 hg38 10kbp up 10kbp down full tx v10 clust.genes vs motifs.rankings), table (motifs-

530 v10nr clust-nr.hgnc-m0.001-o0.0.tbl), and transcription factor list (allTFs hg38.txt). An

531 additional TF list was downloaded

from <u>http://humantfs.ccbr.utoronto.ca/download/v 1.01/TF names v 1.01.txt</u> and the two
lists were merged totaling 2093 TFs.

After the 100 runs were complete, we identified the transcription factors (TFs) that were present in >= 80% of the runs. We then ran pySCENIC an additional 100 times using only the >=80% TFs labeled as transcription factors. The other TFs were retained in the expression matrix, but not labelled as TFs. The TFs that appeared in >= 80% of the second round of runs were isolated as reproducible regulators.

The same resource files and parameters were used in the ROSMAP cohort replication. We filtered the genes to those intersecting those from the Knight ADRC microglia and astrocyte runs. We ran pySCENIC 100 times using the filtered list of TFs for each respective cell state (list used in second round of discovery runs). We isolated the TFs that were present in >= 50% of the runs. We intersected the final lists of discovery TFs with the lists of replication TFs to identify a set of replicable TFs for each cell state.

545

### 546 Co-regulation network clusters

547 Using the TF-target gene matrices for cell state, we identified co-regulation network clusters and visualized them in the UMAP space. The TF-target gene matrix had each of the replicable TFs as 548 549 features, the target genes as elements, and the values were the number of times the target 550 gene was regulated by the TF out of the 100 pySCENIC runs. These values were normalized by 551 the number of times the TF was included in the pySCENIC networks. For example, if TF 1 was in 552 the pySCENIC networks 85 times, all the values would be multiplied by (100/85) to get the 553 normalized value. We then log transformed the values and ran them through a principal 554 component analysis using prcomp, a native R (v4.2.2) function. We then passed the top five 555 principal components (PCs) through the *umap* function from the umap library (v0.2.10.0) to 556 create a two-dimensional representation of the space. The top five PCs were also passed to the 557 makeSNNGraph function from the bluster package (v1.8.0) to create a shared nearest neighbor 558 graph. The resulting graph was passed to the *cluster louvain* function from the igraph package 559 (v1.3.5) to identify clusters of similarly regulated target genes using a resolution of 2. All target

genes in the same cluster as APOE were considered co-regulated with APOE and were evaluatedfor additional AD GWAS genes and for gene set enrichment (Supplementary Table 6).

562

#### 563 **TF regulators for gene clusters**

564 We identified the TFs significantly upregulating the genes in each gene cluster identified in the 565 gene UMAPs. We utilized the normalized, but not log transformed, TF-target gene matrix 566 described in the Gene UMAP clusters section. For each gene cluster at a time, we created a 567 binary vector where 1 indicated the target gene was in the cluster. We then looped through 568 each TF and modelled the TF-target gene values using the binary vector as a covariate. The 569 native glm R function (v4.2.2) was used to train the model with a quasipoisson distribution and 570 log link function. The hits for each cluster were then multiple testing corrected using the 571 Benjamini-Hochberg (BH) method. TFs with a BH corrected p-value less than 0.05 and an 572 estimate greater than zero were considered significant regulators for the gene cluster.

573

#### 574 In silico transcription factor knock-out

575 SCENIC+<sup>17</sup> was recently released with the functionality to knockout a TF and determine the shift 576 in the expression space. We implemented the algorithm proposed in SCENIC+ (v1.0.0, python v3.8.18), which was an adaption from the original method in CellOracle<sup>82</sup>. In summary, this 577 578 method uses the cell by gene expression matrix to train prediction models for each gene. These 579 models allow for the virtual knockout of a TF (TF-KO) by setting the expression of the TF to zero 580 and then using the trained models to predict the shift in target gene expression. The expression 581 shift is then transformed back onto the reduction space and depicted by arrows. 582 By default, SCENIC+ used the GradiantBoostingRegressor from sklearn (v1.3.2) with a learning

rate of 0.01, 500 estimators, and max features set to 0.1 to train prediction models. We included the TFs that were regulating a target gene at least 5% of the time in the model that used TF expression to predict the target gene expression. To correct for the influence of sample proportion on each cell state, we also included the log transformed nuclei counts for the sample in the prediction model. SCENIC+ uses a default of five iterations to propagate the shift across the expression matrix. We extended SCENIC+'s implementation to work with the UMAP space rather than just the PCA space. We also switched the arrows to be drawn by the guiver function

as was found in the CellOracle implementation rather than the streamplot function used bySCENIC+.

592 To extend this method to the UMAP space, we trained a neural network to predict a cell's UMAP 593 coordinates using as input the expression levels of all genes (python v3.11.0). We used the 594 original gene expression matrix (GEM) and UMAP representation for the cell types which 595 included all expression states not just the resting and activated states passed to pySCENIC. First, 596 we log transformed the GEM. We then used the *train test split* function from sklearn (v1.3.2) 597 to split the data into training and testing data (80% training, 20% testing) and stratified by cell 598 state. We then split the training data into training and validation sets (90% training, 10% 599 validation) and once again stratified by cell state. Using the StandardScaler function from 600 sklearn (v1.3.2) we fit and transformed a scaler using the training GEM. This scaler was then 601 used to transform the validation and test GEMs. The sequential neural network was constructed 602 using tensorflow (v2.14.0) and consisted of three layers: two dense layers with the ReLU 603 activation function and an output layer with the same dimensionality as the UMAP data (n=2). 604 The model was compiled with the Adam optimizer and mean squared error loss function. Early 605 stopping was implemented to prevent overfitting with monitoring set to 'val loss' and a 606 patience of 10. The model was then trained on the training data for a maximum of 1000 epochs. 607 The trained model was evaluated on the test GEM. This trained model was used on the TF-KO 608 perturbed matrices to transform the expression shift to the UMAP reduction space. This 609 method was incorporated into a snakemake pipeline so that TF-KO could be performed 610 consistently across TFs, cell states, and cell types.

611

#### 612 **TF knockout differential expression**

We performed a differential expression analysis between the original GEM and perturbed GEM calculated after TF-KO. The original GEM and perturbed GEM were both log transformed. We then filtered out the cells that had zero expression of the TF in the original matrix as these cells have no changes in expression and would skew the results. We then performed a Mann-Whitney rank U test using the *mannwhitneyu* function from scipy (v1.2.2, python v3.11.0) to identify differentially expressed genes. We performed FDR multiple testing correction. Genes

- 619 with a corrected p-value less than 0.05 were considered co-regulated with APOE and were
- 620 evaluated for additional AD GWAS genes and for gene set enrichment (Supplementary Table 6).
- 621

#### 622 Gene set enrichment of genes co-regulated with APOE

- 623 Sets of co-regulated genes where run through enrichment analysis to better understand the
- related function. There were two sources of co-regulated genes, co-regulation network clusters
- and TF-targets, and they were analyzed independently. The gene sets identified by gene clusters
- 626 were run through enrichment analysis using the *enrichr* function from the enrichR package
- 627 (v3.1) in R (v4.2.2) and the TF-targets were run through the *enrichr* function from the gseapy
- 628 package (v0.9.5) in python (v3.11.0). Both used the 2023 GO Biological Process (BP) terms and
- 629 significant associations were those with adjusted p-values less than 0.05.
- 630 The terms from the TF-targets analysis were condensed using rrvgo (v1.6.0), an R package that
- 631 implements the Revigo<sup>83</sup> tool for summarizing GO BP terms. The function *calculateSimMatrix*
- 632 was used to calculate the relationships between the GO BP terms with variable inputs:
- 633 orgdb = "org.Hs.eg.db", ont = "BP", method = "Rel". The terms were then summarized using
- 634 *reduceSimMatrix* and the following variables: score = "Rank", threshold = .7,
- 635 orgdb = "org.Hs.eg.db". The summarized terms or "parentTerms" and their P values were then
- 636 used to make a heatmap. Rows and columns were ordered using dist function
- 637 method = "manhattan".

## 638 Identifying other AD GWAS genes co-regulated APOE

- 639 There were two sources of co-regulated genes, co-regulation network clusters and TF-targets,
- and they were analyzed independently. These gene sets were compared against a list of genes
- 641 within GWAS loci (+/- 500KB of the lead SNP, Supplementary Table 7) and can be found in
- 642 Supplementary Table 6. The Loci for each source were identified and merged. This merged list
- 643 was used to consistently color the genes and loci for each row in the upset plots in Figure 5.

#### 644 Data Availability

The single nucleus data from the Knight ADRC accessed in this study are found in the National

646 Institute on Aging Genetics of Alzheimer's Disease Data Storage Site (NIAGADS) with accession

647 number NG00108 [https://www.niagads.org/datasets/ng00108]. The raw single nucleus data

- 648 from the DIAN brain bank accessed in this study are available under restricted access to
- 649 maintain individual and family confidentiality. These samples contain rare disease-causing
- 650 variants that could be used to identify the participating individuals and families. Access can be
- obtained by request through the online resource request system on the DIAN Website:
- 652 https://dian.wustl.edu/our-research/for-investigators/dian-observational-study-investigator-
- 653 resources/. The ROSMAP single nucleus RNA sequencing data used in this study are available at
- 654 Synapse under Synapse ID syn21125841
- 655 [https://www.synapse.org/#!Synapse:syn21125841/wiki/597278]. The pySCENIC default
- 656 reference data was downloaded from https://resources.aertslab.org/cistarget/: Database
- 657 [https://resources.aertslab.org/cistarget/databases/homo\_sapiens/hg38/refseq\_r80/mc\_v10\_cl
- 658 ust/gene\_based/hg38\_500bp\_up\_100bp\_down\_full\_tx\_v10\_clust.genes\_vs\_motifs.rankings.fea
- 659 ther],
- 660 [https://resources.aertslab.org/cistarget/databases/homo\_sapiens/hg38/refseq\_r80/mc\_v10\_cl
- 661 ust/gene\_based/hg38\_10kbp\_up\_10kbp\_down\_full\_tx\_v10\_clust.genes\_vs\_motifs.rankings.fea
- ther], table [https://resources.aertslab.org/cistarget/motif2tf/motifs-v10nr\_clust-nr.hgnc-
- 663 m0.001-o0.0.tbl], and transcription factor list
- 664 [https://resources.aertslab.org/cistarget/tf\_lists/allTFs\_hg38.txt]. An additional TF list was
- 665 downloaded from [http://humantfs.ccbr.utoronto.ca/download/v\_1.01/TF\_names\_v\_1.01.txt].
- 666 Source data are provided with this paper.

667 Code Availability

668 Custom code used to analyze the snRNA-seq data and datasets generated and/or analyzed in

- the current study are available from the corresponding authors upon request or at
- 670 https://github.com/HarariLab/APOE-GRN.
- 671
- 672

## 673 References

1. Ulrich, J. D. *et al.* ApoE facilitates the microglial response to amyloid plaque pathology. *J.* 

675 *Exp. Med.* **215**, 1047–1058 (2018).

- 676 2. Singh, D. Astrocytic and microglial cells as the modulators of neuroinflammation in
  677 Alzheimer's disease. *J. Neuroinflammation* **19**, 206 (2022).
- 678 3. Eskandari-Sedighi, G. & Blurton-Jones, M. Microglial APOE4: more is less and less is more.
  679 *Mol. Neurodegener.* 18, 99 (2023).
- 4. Fernandez, C. G., Hamby, M. E., McReynolds, M. L. & Ray, W. J. The Role of APOE4 in

Disrupting the Homeostatic Functions of Astrocytes and Microglia in Aging and Alzheimer's
Disease. *Front. Aging Neurosci.* 11, (2019).

- 683 5. Brase, L. *et al.* Single-nucleus RNA-sequencing of autosomal dominant Alzheimer disease
  684 and risk variant carriers. *Nat. Commun.* 14, 2314 (2023).
- 685 6. Zhou, Y. *et al.* Human and mouse single-nucleus transcriptomics reveal TREM2-dependent
  686 and TREM2-independent cellular responses in Alzheimer's disease. *Nat. Med.* 26, 131–142
  687 (2020).
- Kan de Sande, B. *et al.* A scalable SCENIC workflow for single-cell gene regulatory network
  analysis. *Nat. Protoc.* 15, 2247–2276 (2020).
- 690 8. Kunkle, B. W. *et al.* Novel Alzheimer Disease Risk Loci and Pathways in African American
- Individuals Using the African Genome Resources Panel: A Meta-analysis. *JAMA Neurol.* 78,
  102–113 (2021).
- 693 9. Schwartzentruber, J. et al. Genome-wide meta-analysis, fine-mapping and integrative
- 694 prioritization implicate new Alzheimer's disease risk genes. *Nat. Genet.* **53**, 392–402 (2021).
- 10. Lekstrom-Himes, J. & Xanthopoulos, K. G. Biological Role of the CCAAT/Enhancer-binding
- 696 Protein Family of Transcription Factors\*. *J. Biol. Chem.* **273**, 28545–28548 (1998).
- 697 11. Gao, T. *et al.* Transcriptional regulation of homeostatic and disease-associated-microglial
  698 genes by IRF1, LXRβ and CEBPα. *Glia* 67, 1958–1975 (2019).
- 699 12. Xia, Y. *et al.* C/EBPβ is a key transcription factor for APOE and preferentially mediates ApoE4
- expression in Alzheimer's disease. *Mol. Psychiatry* **26**, 6002–6022 (2021).

- 13. Ejarque-Ortiz, A. *et al.* CCAAT/enhancer binding protein delta in microglial activation. *J. Neurosci. Res.* 88, 1113–1123 (2010).
- 703 14. Li, Z. et al. Interferon Regulatory Factor 7 Promoted Glioblastoma Progression and Stemness
- by Modulating IL-6 Expression in Microglia. J. Cancer 8, 207–219 (2017).
- 705 15. Angel, P. & Schorpp-Kistner, M. Jun/Fos. in Encyclopedic Reference of Genomics and
- 706 *Proteomics in Molecular Medicine* 928–935 (Springer, Berlin, Heidelberg, 2006).
- 707 doi:10.1007/3-540-29623-9\_4560.
- 16. Roman, C. *et al.* Thyroid hormones upregulate apolipoprotein E gene expression in
  astrocytes. *Biochem. Biophys. Res. Commun.* 468, 190–195 (2015).
- 710 17. Bravo González-Blas, C. *et al.* SCENIC+: single-cell multiomic inference of enhancers and
  711 gene regulatory networks. *Nat. Methods* 20, 1355–1367 (2023).
- 18. Honma, S. *et al.* Dec1 and Dec2 are regulators of the mammalian molecular clock. *Nature*419, 841–844 (2002).
- 19. Kawamoto, T. *et al.* A novel autofeedback loop of Dec1 transcription involved in circadian
  rhythm regulation. *Biochem. Biophys. Res. Commun.* **313**, 117–124 (2004).
- 716 20. Cho, Y. et al. The Basic Helix-Loop-Helix Proteins Differentiated Embryo Chondrocyte (DEC) 1
- and DEC2 Function as Corepressors of Retinoid X Receptors. *Mol. Pharmacol.* 76, 1360–1369
  (2009).
- 719 21. Yoshitane, H. *et al.* Functional D-box sequences reset the circadian clock and drive mRNA
  720 rhythms. *Commun. Biol.* 2, 1–10 (2019).
- 721 22. Podlesny-Drabiniok, A. et al. BHLHE40/41 regulate macrophage/microglia responses
- associated with Alzheimer's disease and other disorders of lipid-rich tissues.
- 723 2023.02.13.528372 Preprint at https://doi.org/10.1101/2023.02.13.528372 (2023).
- 724 23. Yoshida, H., Matsui, T., Yamamoto, A., Okada, T. & Mori, K. XBP1 mRNA is induced by ATF6
- and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. *Cell* 107, 881–891 (2001).
- 727 24. Pan, Y. et al. 12-h clock regulation of genetic information flow by XBP1s. PLOS Biol. 18,
- 728 e3000580 (2020).

- 729 25. Foulkes, N. S., Borjigin, J., Snyder, S. H. & Sassone-Corsi, P. Transcriptional control of
- circadian hormone synthesis via the CREM feedback loop. *Proc. Natl. Acad. Sci.* 93, 14140–
  14145 (1996).
- 26. Lech, K. *et al.* Dissecting Daily and Circadian Expression Rhythms of Clock-Controlled Genes
  in Human Blood. *J. Biol. Rhythms* **31**, 68–81 (2016).
- 734 27. Sun, N. *et al.* Human microglial state dynamics in Alzheimer's disease progression. *Cell* 186,
  735 4386-4403.e29 (2023).
- 736 28. Yan, D. *et al.* SIRT1/FOXO3-mediated autophagy signaling involved in manganese-induced
  737 neuroinflammation in microglia. *Ecotoxicol. Environ. Saf.* 256, 114872 (2023).
- 738 29. López-Sánchez, N., Ramón-Landreau, M., Trujillo, C., Garrido-García, A. & Frade, J. M. A
- 739 Mutant Variant of E2F4 Triggers Multifactorial Therapeutic Effects in 5xFAD Mice. *Mol.*
- 740 *Neurobiol.* **59**, 3016–3039 (2022).
- 741 30. Bräuer, A. U., Nitsch, R. & Savaskan, N. E. Identification of macrophage/microglia activation
- factor (MAF) associated with late endosomes/lysosomes in microglial cells. *FEBS Lett.* 563,
  41–48 (2004).
- 744 31. Tocco, C., Bertacchi, M. & Studer, M. Structural and Functional Aspects of the
- 745 Neurodevelopmental Gene NR2F1: From Animal Models to Human Pathology. *Front. Mol.*746 *Neurosci.* 14, (2021).
- 32. Bertacchi, M. *et al.* Mouse Nr2f1 haploinsufficiency unveils new pathological mechanisms of
  a human optic atrophy syndrome. *EMBO Mol. Med.* **11**, e10291 (2019).
- 749 33. Zhou, L. *et al.* Degeneration and energy shortage in the suprachiasmatic nucleus underlies
- the circadian rhythm disturbance in ApoE-/- mice: implications for Alzheimer's disease. *Sci. Rep.* 6, 36335 (2016).
- 34. Wheeler, M. A. *et al.* MAFG-driven astrocytes promote CNS inflammation. *Nature* 578, 593–
  599 (2020).
- 754 35. Szewczyk, L. M. *et al.* Astrocytic β-catenin signaling via TCF7L2 regulates synapse
- development and social behavior. *Mol. Psychiatry* 1–17 (2023) doi:10.1038/s41380-023-
- 756 02281-y.

- 757 36. Lee, H. *et al.* ApoE4-dependent lysosomal cholesterol accumulation impairs mitochondrial
- homeostasis and oxidative phosphorylation in human astrocytes. *Cell Rep.* 42, 113183
  (2023).
- 37. Williams, H. C. *et al.* APOE alters glucose flux through central carbon pathways in astrocytes. *Neurobiol. Dis.* **136**, 104742 (2020).
- 762 38. Drobny, A. et al. The role of lysosomal cathepsins in neurodegeneration: Mechanistic
- insights, diagnostic potential and therapeutic approaches. *Biochim. Biophys. Acta BBA Mol. Cell Res.* 1869, 119243 (2022).
- 765 39. Fu, L. *et al.* Enhanced expression of FCER1G predicts positive prognosis in multiple
  766 myeloma. *J. Cancer* 11, 1182–1194 (2020).
- 40. Fuller, J. P., Stavenhagen, J. B. & Teeling, J. L. New roles for Fc receptors in
- 768 neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease. *Front. Neurosci.*769 **8**, 235 (2014).
- 41. Jin, J. *et al.* Shared Molecular Mechanisms between Alzheimer's Disease and Periodontitis
  Revealed by Transcriptomic Analysis. *BioMed Res. Int.* 2021, 6633563 (2021).
- 42. Lanfranco, M. F., Ng, C. A. & Rebeck, G. W. ApoE Lipidation as a Therapeutic Target in
  Alzheimer's Disease. *Int. J. Mol. Sci.* 21, 6336 (2020).
- 43. Martín, M. G., Pfrieger, F. & Dotti, C. G. Cholesterol in brain disease: sometimes determinant
  and frequently implicated. *EMBO Rep.* 15, 1036–1052 (2014).
- 44. Iyer, D. N. *et al.* Pathophysiological roles of myristoylated alanine-rich C-kinase substrate
  (MARCKS) in hematological malignancies. *Biomark. Res.* 9, 34 (2021).
- 45. Issara-Amphorn, J. *et al.* Myristoylated, alanine-rich C-kinase substrate (MARCKS) regulates
  toll-like receptor 4 signaling in macrophages. *Sci. Rep.* 13, 19562 (2023).
- 780 46. Turco, E. et al. Reconstitution defines the roles of p62, NBR1 and TAX1BP1 in ubiquitin
- 781 condensate formation and autophagy initiation. *Nat. Commun.* **12**, 5212 (2021).
- 47. Wu, C.-H. *et al.* Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis.
- 783 *Nature* **488**, 499–503 (2012).

- 48. Frantzi, M. et al. Silencing of Profilin-1 suppresses cell adhesion and tumor growth via
- predicted alterations in integrin and Ca 2+ signaling in T24M-based bladder cancer models.
  Oncotarget 7, 70750–70768 (2016).
- 49. Gallo, M. *et al.* MISC-1/OGC links mitochondrial metabolism, apoptosis and insulin
  secretion. *PloS One* 6, e17827 (2011).
- 50. Keckesova, Z. *et al.* LACTB is a tumour suppressor that modulates lipid metabolism and cell
  state. *Nature* 543, 681–686 (2017).
- 51. Tachibana, H. *et al.* The plasma membrane of focal adhesions has a high content of
  cholesterol and phosphatidylcholine with saturated acyl chains. *J. Cell Sci.* 136, jcs260763
  (2023).
- 52. Liu, C.-C. *et al.* Peripheral apoE4 enhances Alzheimer's pathology and impairs cognition by
  compromising cerebrovascular function. *Nat. Neurosci.* 25, 1020–1033 (2022).

53. Wang, H. et al. Regulation of Neuroinflammation by Astrocyte-Derived Cholesterol.

- 797 http://biorxiv.org/lookup/doi/10.1101/2022.12.12.520161 (2022)
- 798 doi:10.1101/2022.12.12.520161.
- 54. Hanisch, U.-K. Microglia as a source and target of cytokines. *Glia* **40**, 140–155 (2002).
- 55. Choi, S. S., Lee, H. J., Lim, I., Satoh, J. & Kim, S. U. Human Astrocytes: Secretome Profiles of
  Cytokines and Chemokines. *PLOS ONE* 9, e92325 (2014).
- 56. Sofroniew, M. V. Multiple Roles for Astrocytes as Effectors of Cytokines and Inflammatory
  Mediators. *The Neuroscientist* 20, 160–172 (2014).
- 804 57. van der Kant, R. *et al.* Cholesterol Metabolism Is a Druggable Axis that Independently
  805 Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer's Disease Neurons. *Cell Stem Cell*806 24, 363-375.e9 (2019).
- 807 58. Wang, H. *et al.* Regulation of beta-amyloid production in neurons by astrocyte-derived
  808 cholesterol. *Proc. Natl. Acad. Sci. U. S. A.* **118**, e2102191118 (2021).
- 59. Lee, S.-I. *et al.* APOE4-carrying human astrocytes oversupply cholesterol to promote
- 810 neuronal lipid raft expansion and Aβ generation. *Stem Cell Rep.* **16**, 2128–2137 (2021).

- 811 60. Ehehalt, R., Keller, P., Haass, C., Thiele, C. & Simons, K. Amyloidogenic processing of the
- Alzheimer β-amyloid precursor protein depends on lipid rafts. *J. Cell Biol.* 160, 113–123
  (2003).
- 814 61. Mattiola, I., Mantovani, A. & Locati, M. The tetraspan MS4A family in homeostasis,
  815 immunity, and disease. *Trends Immunol.* 42, 764–781 (2021).
- 816 62. Koepsell, H. Glucose transporters in brain in health and disease. *Pflüg. Arch. Eur. J. Physiol.*
- **472**, 1299–1343 (2020).
- 818 63. Yan, Q. *et al.* Mechanistic insights into GLUT1 activation and clustering revealed by super819 resolution imaging. *Proc. Natl. Acad. Sci.* 115, 7033–7038 (2018).
- 64. Li, D., Zhang, J. & Liu, Q. Brain cell type-specific cholesterol metabolism and implications for
  learning and memory. *Trends Neurosci.* 45, 401–414 (2022).
- 65. Alessandri, B., Gugliotta, M., Levasseur, J. E. & Bullock, M. R. Lactate and glucose as energy
- substrates and their role in traumatic brain injury and therapy. *Future Neurol.* 4, 209–228
  (2009).
- 66. Graybeal, J. J. *et al.* Human ApoE ε4 Alters Circadian Rhythm Activity, IL-1β, and GFAP in
  CRND8 Mice. *J. Alzheimers Dis.* 43, 823–834 (2014).
- 67. Wu, L., Zhang, X. & Zhao, L. Human ApoE Isoforms Differentially Modulate Brain Glucose and
  Ketone Body Metabolism: Implications for Alzheimer's Disease Risk Reduction and Early
- 829 Intervention. J. Neurosci. **38**, 6665–6681 (2018).
- 68. Ioannou, M. S. *et al.* Neuron-Astrocyte Metabolic Coupling Protects against Activity-Induced
  Fatty Acid Toxicity. *Cell* **177**, 1522-1535.e14 (2019).
- 69. Ke, P. *et al.* Relationship between circadian genes and memory impairment caused by sleep
  deprivation. *PeerJ* 10, e13165 (2022).
- 834 70. Niu, L. *et al.* Chronic sleep deprivation altered the expression of circadian clock genes and
- aggravated Alzheimer's disease neuropathology. *Brain Pathol.* **32**, e13028 (2022).
- 836 71. Ni, J. *et al.* An impaired intrinsic microglial clock system induces neuroinflammatory
- alterations in the early stage of amyloid precursor protein knock-in mouse brain. J.
- 838 *Neuroinflammation* **16**, 173 (2019).

- 839 72. Guzmán, M. & Blázquez, C. Ketone body synthesis in the brain: possible neuroprotective
  840 effects. *Prostaglandins Leukot. Essent. Fatty Acids* **70**, 287–292 (2004).
- 73. Zhang, Z. *et al.* Circadian rhythm and atherosclerosis (Review). *Exp. Ther. Med.* 20, 96
  (2020).
- 74. Lam, M. T. Y. *et al.* Rev-Erbs repress macrophage gene expression by inhibiting enhancerdirected transcription. *Nature* 498, 511–515 (2013).
- 845 75. Lee, J. *et al.* Microglial REV-ERBα regulates inflammation and lipid droplet formation to drive
  846 tauopathy in male mice. *Nat. Commun.* 14, 5197 (2023).
- 847 76. Eitan, E., Suire, C., Zhang, S. & Mattson, M. P. Impact of lysosome status on extracellular
  848 vesicle content and release. *Ageing Res. Rev.* 32, 65–74 (2016).
- 77. Nguyen, M.-A. *et al.* Extracellular Vesicles Secreted by Atherogenic Macrophages Transfer
  MicroRNA to Inhibit Cell Migration. *Arterioscler. Thromb. Vasc. Biol.* 38, 49–63 (2018).
- 78. Bouchareychas, L. *et al.* Macrophage Exosomes Resolve Atherosclerosis by Regulating
  Hematopoiesis and Inflammation via MicroRNA Cargo. *Cell Rep.* 32, 107881 (2020).
- 853 79. Gabrielli, M., Raffaele, S., Fumagalli, M. & Verderio, C. The multiple faces of extracellular
- vesicles released by microglia: Where are we 10 years after? *Front. Cell. Neurosci.* 16,
- 855 (2022).
- 856 80. Strauss, K. *et al.* Exosome Secretion Ameliorates Lysosomal Storage of Cholesterol in
  857 Niemann-Pick Type C Disease\*. *J. Biol. Chem.* 285, 26279–26288 (2010).
- 81. Aibar, S. *et al.* SCENIC: single-cell regulatory network inference and clustering. *Nat. Methods*14, 1083–1086 (2017).
- 860 82. Kamimoto, K. *et al.* Dissecting cell identity via network inference and in silico gene
  861 perturbation. *Nature* 614, 742–751 (2023).
- 862 83. Supek, F., Bošnjak, M., Škunca, N. & Šmuc, T. REVIGO Summarizes and Visualizes Long Lists
  863 of Gene Ontology Terms. *PLOS ONE* 6, e21800 (2011).

864

865

## 866 Acknowledgments

- 867 Doctors Bruno A. Benitez, and Oscar Harari contributed equally to this work as co-senior
- 868 authors. Data sharing for this project were supported by The Dominantly Inherited Alzheimer
- 869 Network (DIAN, U19AG032438), funded by the National Institute on Aging (NIA), the
- 870 Alzheimer's Association (SG-20-690363-DIAN), the German Center for Neurodegenerative
- 871 Diseases (DZNE), Raul Carrea Institute for Neurological Research (FLENI), Partial support by the
- 872 Research and Development Grants for Dementia from Japan Agency for Medical Research and
- 873 Development, AMED, and the Korea Health Technology R&D Project through the Korea Health
- 874 Industry Development Institute (KHIDI), Spanish Institute of Health Carlos III (ISCIII), Canadian
- 875 Institutes of Health Research (CIHR), Canadian Consortium of Neurodegeneration and Aging,
- 876 Brain Canada Foundation, and Fonds de Recherche du Québec Santé. DIAN Study investigators
- 877 have reviewed this manuscript for scientific content and consistency of data interpretation with
- 878 previous DIAN Study publications. We acknowledge the altruism of the participants and their
- 879 families and the contributions of the DIAN research and support staff at each of the
- 880 participating sites for their contributions to this study.
- The results published here are partly based on data obtained from the AD Knowledge Portal
- 882 (https://adknowledgeportal.org). Study data were provided by the Rush Alzheimer's Disease
- 883 Center, Rush University Medical Center, Chicago. Data collection was supported through funding
- by NIA grants P30AG10161 (ROS), R01AG15819 (ROSMAP; genomics and RNAseq), R01AG17917
- 885 (MAP), R01AG30146, R01AG36042 (5hC methylation, ATACseq), RC2AG036547 (H3K9Ac),
- 886 R01AG36836 (RNAseq), R01AG48015 (monocyte RNAseq) RF1AG57473 (single nucleus
- 887 RNAseq), U01AG32984 (genomic and whole exome sequencing), U01AG46152 (ROSMAP AMP-
- AD, targeted proteomics), U01AG46161(TMT proteomics), U01AG61356 (whole genome
- sequencing, targeted proteomics, ROSMAP AMP-AD), the Illinois Department of Public Health
- 890 (ROSMAP), and the Translational Genomics Research Institute (genomic). Additional phenotypic
- 891 data can be requested at www.radc.rush.edu.
- 892 This work was possible thanks to the following governmental grants from the National Institute
- 893 of Health: NIA R01AG057777 (OH), R56AG067764 (OH), U01AG072464 (OH), R01AG074012
- 894 (OH), U19AG032438 (RJB), NINDS R01NS118146 (BAB), R21NS127211 (BAB), NIA T32AG058518
- 895 (LB), O.H. is an Archer Foundation Research Scientist.
- 896 This work was supported by access to equipment made possible by the Departments of
- 897 Neurology and Psychiatry at Washington University School of Medicine.
- The funders of the study had no role in the collection, analysis, or interpretation of data, in the writing of the report, or in the decision to submit the paper for publication.
- Figure 1 was created with BioRender.com. Bing Copilot was used to improve grammar and flowof text.

# 902 Author Contributions

- 903 L.B. performed the quality control, bioinformatic analyses, interpreted the results, created the
- 904 figures, and wrote the manuscript. Y.Y. ran the pySCENIC analyses. E.M. was involved in the DIAN
- sample collection, profiling and provided a critical review of the manuscript. O.H. and B.A.B.
- 906 were involved in experiment design, analysis, data interpretation, intellectual contribution, and
- 907 manuscript writing and review.

## 908 Competing Interests

- 909 E.M. receives Grant Funding from NIA; Institutional funding from Eli Lilly, Hoffmann-La Roche,
- 910 Eisai. He is a DSMB member (paid directly) for Alector; Eli Lilly; a Scientific Advisory Board
- 911 Member (paid directly) for Alzamend, Fondation Alzheimer. He acts as a Consultant/Advisor for
- 912 Sage Therapeutics, Eli Lilly, Sanofi, AstraZeneca, Hoffmann La-Roche. The other authors have no
- 913 conflicts of interest to disclose.
- 914 Supplementary Information
- 915 Supplementary Information .pdf file